In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over ...

HIMS Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.